Illumina, Inc. vs Schlumberger NV — how do they compare? Illumina, Inc. trades at $265 (market cap $40.43B), while Schlumberger NV trades at $49 (market cap $71.18B). The key difference: Schlumberger NV is the larger of the two by market cap, and Schlumberger NV pays a 2.46% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Schlumberger NV for 99 Days on average.
| ILMN | SLB | |
|---|---|---|
Market Cap | $40.43B | $71.18B |
Volume | 2,948,626 | 14,872,321 |
Sector | Health | Energy |
52-Week High | $293.69 | $60.10 |
52-Week Low | $91.00 | $31.72 |
Typical Hold Time | 83 Days | 99 Days |
Enterprise Value | $41.79B | $79.91B |
Dividend Yield | — | 2.46% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
SLB trades at $48.98, down 2.04% with bearish technical signals despite strong analyst support. The company maintains solid profitability with 8.53% net margin and 13.37% ROE, though recent revenue and earnings show slight contraction. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility and expansion in key energy markets.
Wall Street remains bullish with 85% buy ratings and $64.58 price target implying 32% upside. However, declining profit margins and bearish technical indicators suggest near-term pressure. The stock offers value at current levels for investors comfortable with energy sector volatility and execution risks on new contracts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →